Ticagrelor in Patients with Stable Coronary Disease and Diabetes

In patients with stable coronary artery disease and diabetes mellitus who have not had a myocardial infarction or stroke, the addition of ticagrelor to aspirin was evaluated for its efficacy and safety. This randomized, double blind trial assigned 19,220 patients to receive either ticagrelor plus aspirin or placebo plus aspirin. The primary efficacy outcome was a composite of cardiovascular death, myocardial infarction, or stroke, while the primary safety outcome was major bleeding. Results showed a lower incidence of ischemic cardiovascular events in the ticagrelor group (7.7% vs. 8.5%; hazard ratio, 0.90; P=0.04) but a higher incidence of major bleeding (2.2% vs. 1.0%; hazard ratio, 2.32; P<0.001). The study concluded that ticagrelor reduced ischemic events but increased bleeding risk in this patient population.

In patients with stable coronary artery disease and diabetes mellitus who have not had a myocardial infarction or stroke, the addition of ticagrelor to aspirin was evaluated for its efficacy and safety. This randomized, double blind trial assigned 19,220 patients to receive either ticagrelor plus aspirin or placebo plus aspirin. The primary efficacy outcome was a composite of cardiovascular death, myocardial infarction, or stroke, while the primary safety outcome was major bleeding. Results showed a lower incidence of ischemic cardiovascular events in the ticagrelor group (7.7% vs. 8.5%; hazard ratio, 0.90; P=0.04) but a higher incidence of major bleeding (2.2% vs. 1.0%; hazard ratio, 2.32; P<0.001). The study concluded that ticagrelor reduced ischemic events but increased bleeding risk in this patient population.